Evidence map›Paper›PMID 39397086›Full record

ArticleArchives of gynecology and obstetrics2025

Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer.

Violante Di Donato, Giuseppe Caruso, Tullio Golia D'Augè, Giorgia Perniola, Innocenza Palaia, Federica Tomao, Ludovico Muzii, Angelina Pernazza, Carlo Della Rocca, Giorgio Bogani and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Violante Di DonatoDepartment of Maternal and Child Health and Urological Sciences, University of Rome Sapienza, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy. violante.didonato@uniroma1.it.
Giuseppe CarusoDepartment of Maternal and Child Health and Urological Sciences, University of Rome Sapienza, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.
Tullio Golia D'AugèDepartment of Maternal and Child Health and Urological Sciences, University of Rome Sapienza, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.ORCID 0000-0002-1018-3088
Giorgia PerniolaDepartment of Maternal and Child Health and Urological Sciences, University of Rome Sapienza, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.
Innocenza PalaiaDepartment of Maternal and Child Health and Urological Sciences, University of Rome Sapienza, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.
Federica TomaoDepartment of Maternal and Child Health and Urological Sciences, University of Rome Sapienza, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.
Ludovico MuziiDepartment of Maternal and Child Health and Urological Sciences, University of Rome Sapienza, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.
Angelina PernazzaDepartment of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Rome, Italy.
Carlo Della RoccaDepartment of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Rome, Italy.
Giorgio BoganiGynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy.
Pierluigi Benedetti PaniciDepartment of Maternal and Child Health and Urological Sciences, University of Rome Sapienza, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy.
Andrea GianniniUnit of Gynecology, Department of Surgical and Medical Sciences and Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine the prognostic impact of microscopic residual disease after neoadjuvant chemotherapy (NACT) in patients undergoing interval debulking surgery (IDS) for advanced epithelial ovarian cancer (AEOC).

methodsPatients affected by FIGO stage IIIC-IV ovarian cancer undergoing IDS between October 2010 and April 2016 were selected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier analysis.

resultsIn total, 98 patients were identified. Four patients (4.1%) were considered inoperable. Overall, 67 patients (out of 94; 71.3%) had macroscopic disease, equating Chemotherapy Response Score (CRS) 1 and 2, 7 (7.4%) had microscopic residuals, equating CRS3, rare CRS2, while 20 (21.3%) had both microscopic and macroscopic disease. Median OS and PFS were, respectively, 44 and 14 months in patients with no macroscopic residual disease (RD = 0) compared to 25 and 6 months, in patients with RD > 0 (OS: p = 0.001; PFS: p = 0.002). The median PFS was 9 months compared to 14 months for patients with more or less than 3 areas of microscopic disease at final pathologic evaluation (p = 0.04). The serum Ca125 dosage after NACT was higher in patients with RD > 0 compared to those without residue (986.31 ± 2240.7 µg/mL vs 215.72 ± 349.5 µg/mL; p = 0.01).

conclusionEven in the absence of macroscopic disease after NACT, the persistence of microscopic residuals predicts a poorer prognosis among AEOC patients undergoing IDS, with a trend towards worse PFS for patients with more than three affected areas. Removing all fibrotic residuals eventually hiding microscopic disease during IDS represents the key to improving the prognosis of these patients.

Indexed as

Carcinoma, Ovarian EpithelialCytoreduction Surgical ProceduresOvarian NeoplasmsAdultAgedChemotherapy, AdjuvantFemaleHumansKaplan-Meier EstimateMiddle AgedNeoadjuvant TherapyNeoplasm, ResidualNeoplasm StagingPrognosisProgression-Free SurvivalRetrospective StudiesInterval debulking surgeryMicroscopic residual diseaseNeoadjuvant chemotherapyOvarian cancerResidual tumor

Identifiers

PMID39397086
PMCPMC11890345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.